Results 271 to 280 of about 18,597 (294)
Some of the next articles are maybe not open access.
Preparative Biochemistry & Biotechnology, 2020
Echinocandin B, a kind of antimycotic with cyclic lipo-hexapeptides, was produced by fermentation with Aspergillus nidulans using fructose as main carbon source.
Zhong-Ce Hu +4 more
semanticscholar +1 more source
Echinocandin B, a kind of antimycotic with cyclic lipo-hexapeptides, was produced by fermentation with Aspergillus nidulans using fructose as main carbon source.
Zhong-Ce Hu +4 more
semanticscholar +1 more source
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
Echinocandins for the Nursery: An Update
Current Drug Metabolism, 2013As the incidence rates of neonatal invasive fungal infection (IFI) have been increasing over the last years, research efforts have been addressed towards identifying both effective preventative strategies, and efficacious and well-tolerated antifungal drugs.
Michael Cohen-Wolkowiez +7 more
openaire +3 more sources
Echinocandins: Are They All The Same?
Journal of Chemotherapy, 2011The discovery of echinocandins, and their development and approval, was hailed as a significant addition to our antifungal armamentarium, previously predominated by polyenes and azoles. To date, three echinocandins (anidulafungin, caspofungin, and micafungin) have been approved by the U.S.
Mahmoud A. Ghannoum +4 more
openaire +3 more sources
Expert Opinion on Therapeutic Patents, 2002
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +2 more sources
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +2 more sources
Pharmacokinetics/pharmacodynamics of echinocandins
European Journal of Clinical Microbiology & Infectious Diseases, 2004The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. The favorable pharmacokinetic profile of the echinocandins has been elucidated in animal and human studies. The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme
openaire +3 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Black Regina M
openaire +2 more sources
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Black Regina M
openaire +2 more sources
Echinocandins: The Newest Class of Antifungals
Annals of Pharmacotherapy, 2009Objective: To review the mechanism of action, antifungal spectrum of activity, pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of the echinocandins. Data Sources: A MEDLINE search (1982–May 2009) was conducted for articles published in the English language using the key words caspofungin, micafungin, anidulafungin, and echinocandins ...
Sucher, Allana J. +2 more
openaire +3 more sources
Anidulafungin: an echinocandin antifungal
Expert Opinion on Investigational Drugs, 2004Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
openaire +2 more sources
Molecular Detection of Resistance to Echinocandins
2016In the last years, life-threatening fungal diseases have increased significantly, due to the rising number of human individuals susceptible to fungal infections, which are in part complicated by the emergence of antifungal drug-resistant pathogens.
Posteraro, Brunella +3 more
openaire +3 more sources